menu
    • menu
    [{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Affimed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Partnership","leadProduct":"AB-101","moa":"||CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Artiva Biotherapeutics \/ Artiva Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Artiva Biotherapeutics \/ Artiva Biotherapeutics"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Affimed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AB-101","moa":"||CD16A\/30","graph1":"Oncology","graph2":"Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Artiva Biotherapeutics \/ Artiva Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Artiva Biotherapeutics \/ Artiva Biotherapeutics"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"GC Cell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"GCC2005","moa":"CD5","graph1":"Oncology","graph2":"Phase I","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Artiva Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Artiva Biotherapeutics \/ Artiva Biotherapeutics"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Affimed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AFM13","moa":"Immunoglobulin gamma Fc receptor IIIA (FCGR3A)","graph1":"Oncology","graph2":"Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Artiva Biotherapeutics \/ Artiva Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Artiva Biotherapeutics \/ Artiva Biotherapeutics"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Artiva Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AB-101","moa":"PD-L1","graph1":"Immunology","graph2":"Phase I","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Artiva Biotherapeutics \/ Artiva Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Artiva Biotherapeutics \/ Artiva Biotherapeutics"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AB-101","moa":"PD-L1","graph1":"Nephrology","graph2":"Phase I","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Artiva Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Artiva Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AB-101","moa":"||PD-L1","graph1":"Nephrology","graph2":"Phase I","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Artiva Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Artiva Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AB-101","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AB-101","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"AB-101","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Artiva Biotherapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Artiva Biotherapeutics \/ Jefferies"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"AB-101","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AB-101","moa":"||PD-L1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Artiva Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series A Financing","leadProduct":"AB-101","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ 5Am Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ 5Am Ventures"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Artiva Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Artiva Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Collaboration","leadProduct":"AB-MK-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artiva Biotherapeutics","amount2":1.8700000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.8700000000000001,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Artiva Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MG4101","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Artiva Biotherapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Artiva Biotherapeutics

    Menu

    Artiva Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MG4101

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AlloNK® + Rituximab Safety & Efficacy In Relapsing B-Cell Dependent Rheumatologic Diseases

                            Details : MG4101 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Arthritis, Rheumatoid.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 25, 2025

                            Lead Product(s) : MG4101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GCC2005

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : GC Cell

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Ma...

                            Details : GCC2005 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, T-Cell.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 21, 2024

                            Lead Product(s) : GCC2005

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : GC Cell

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-101

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Recipient : IRIS Research and Development, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell...

                            Details : AB-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis, Rheumatoid.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 03, 2024

                            Lead Product(s) : AB-101

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Recipient : IRIS Research and Development, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-101,Acimtamig,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Jefferies

                            Deal Size : $167.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Artiva upsizes IPO to $167 million as NK cell therapy biotech heads to Nasdaq

                            Details : The net proceeds will be used to fund the clinical development of the company's lead product AlloNK (AB-101), which is being evaluated for the treatment of r/r Hodgkin Lymphoma.

                            Product Name : AlloNK

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 18, 2024

                            Lead Product(s) : AB-101,Acimtamig,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Jefferies

                            Deal Size : $167.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-101,Cyclophosphamide,Rituximab

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Artiva Biotherapeutics Receives FDA Fast Track Designation for AlloNK® in Lupus Nephritis

                            Details : AlloNK (AB-101) is an allogeneic NK cell therapy designed to enhance antibody-dependent cellular cytotoxicity in combination with rituximab or obinutuzumab for treating lupus nephritis.

                            Product Name : AlloNK

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 22, 2024

                            Lead Product(s) : AB-101,Cyclophosphamide,Rituximab

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-101

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nep...

                            Details : AB-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lupus Nephritis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 20, 2024

                            Lead Product(s) : AB-101

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-101,Rituximab

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with ...

                            Details : AlloNK (AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with Combination with Rituximab in Lupus Nephritis.

                            Product Name : AlloNK

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 16, 2023

                            Lead Product(s) : AB-101,Rituximab

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AFM13

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Affimed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL

                            Details : AFM13 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hodgkin Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 01, 2023

                            Lead Product(s) : AFM13

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Affimed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acimtamig,AB-101

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Affimed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therap...

                            Details : AFM13 is a first-in-class innate cell engager (ICE®) that uniquely leverags the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages to destroy CD30-positive hematologic tumors.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 23, 2023

                            Lead Product(s) : Acimtamig,AB-101

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Affimed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

                            Details : AB-201 is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 10, 2023

                            Lead Product(s) : AB-201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth